Sector: Healthcare | Industry: Healthcare Facilities & Services |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 4400 Biscayne Blvd. MIAMI FL 33137 |
Tel: | 1-310-6917100 |
Website: | https://www.opko.com |
IR: | See website |
Key People | ||
Phillip Frost Chairman of the Board, Chief Executive Officer | Elias A. Zerhouni President, Vice Chairman of the Board | Jane H. Hsiao Vice Chairman of the Board, Chief Technical Officer |
Adam E. Logal Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Treasurer | Charles W. Bishop Chief Executive Officer of OPKO Renal | Tony F. Cruz Chief Executive Officer, Transition Therapeutics, Inc |
Steven D. Rubin Executive Vice President - Administration, Director | Gary J. Nabel Chief Innovation Officer, Director |
Business Overview |
OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company. The Company's diagnostics segment consists of the clinical laboratory operations of BioReference Health, LLC (BioReference), its point-of-care operations. Its pharmaceutical segment consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. Through BioReference, it operates specialized laboratory divisions, such as GenPath (Urology), GenPath (Oncology), and GenPath (Women's Health). It has two commercial stage pharmaceutical products and several pharmaceutical compounds and technologies in various stages of research and development for a range of indications and conditions, including Rayaldee, Rayaldee, Oxyntomodulin, Biologics, NGENLA Somatrogon, and Factor VIIa-CTP. It develops and manufactures specialty active pharmaceutical ingredients (APIs) through FineTech Pharmaceutical, Ltd. |
Financial Overview |
For the fiscal year ended 31 December 2023, OPKO Health Inc revenues decreased 14% to $863.5M. Net loss decreased 42% to $188.9M. Revenues reflect Diagnostics segment decrease of 32% to $515.3M, United States segment decrease of 24% to $597.8M. Lower net loss reflects Pharmaceutical segment income totaling $41.2M vs. loss of $13M, Diagnostics segment loss decrease of 10% to $155.6M. |
Employees: | 3,930 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $1,035M as of Dec 31, 2023 |
Annual revenue (TTM): | $863.49M as of Dec 31, 2023 |
EBITDA (TTM): | -$51.69M as of Dec 31, 2023 |
Net annual income (TTM): | -$188.86M as of Dec 31, 2023 |
Free cash flow (TTM): | -$44.47M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | $163.55M as of Dec 31, 2023 |
Shares outstanding: | 696,991,677 as of Feb 13, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |